Author

Hotaka Maruyama

Institution: Pharmaceuticals and Medical Devices Agency

Observed institutions: Keio University, Keio University Hospital, Pharmaceuticals and Medical Devices Agency

ORCID: 0009-0006-3202-4869

Observed ORCID: 0009-0006-3202-4869

OpenAlex ID: A5030030222

Cardiovascular Risk of Romosozumab vs. Teriparatide: A Cohort Study Using Japan’s National Claims Database

2025 · Hotaka Maruyama, Eiko Iwasa, et al. · Clinical Pharmacology & Therapeutics · 11

Real-world prescription of anti-COVID-19 drugs in hospitalized patients with COVID-19 in Japan

2024 · Haruka Shida, Maki Komamine, et al. · PLoS ONE · 5

Does Use of a Biosimilar Product Reduce the Expenditure of Patients?

2016 · Hotaka Maruyama, Shinji Miyake, et al. · Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) · 2

Safety Comparison of Risk of Liver Dysfunction between Generic and Brand Statin Drugs Marketed in Japan: A Cohort Study Using MID-NET®

2025 · Hotaka Maruyama, Yuki Kinoshita, et al. · Therapeutic Innovation & Regulatory Science · 1

Establishment of reliable identification algorithms for acute heart failure or acute exacerbation of chronic heart failure using clinical data from a medical information database network

2025 · Ryusuke Inoue, Masaharu Nakayama, et al. · Frontiers in Cardiovascular Medicine · 1

Development and Validation of Interstitial Lung Disease Identification Algorithms in Japan’s Post-Marketing Drug Safety Surveillance Platform, MID-NET®

2025 · Masatoshi Tanigawa, Wakako Horiki, et al.

Risk of liver dysfunction with ACE inhibitors based on real-world data from the MID-NET® in Japan

2025 · Yuki Kinoshita, Takashi Ando, et al. · Hypertension Research

Works count: 7

Citation count: 20

H-index: 2

I10-index: 1